Ken Griffin Nuvalent, Inc. Call Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$67.44 - $112.17 $3.42 Million - $5.69 Million	-50,700 Reduced 82.17%	11,000 $1.13 Million
Q2 2024 Aug 14, 2024	SELL	$62.76 - $81.61 $696,636 - $905,871	-11,100 Reduced 15.25%	61,700 $4.68 Million
Q1 2024 May 15, 2024	BUY	$72.35 - $88.99 $3.44 Million - $4.23 Million	47,500 Added 187.75%	72,800 $5.47 Million
Q4 2023 Feb 14, 2024	BUY	$42.42 - $80.28 $415,716 - $786,744	9,800 Added 63.23%	25,300 $1.86 Million
Q3 2023 Nov 14, 2023	BUY	$39.12 - $49.85 $594,624 - $757,720	15,200 Added 5066.67%	15,500 $712,000
Q2 2023 Aug 14, 2023	SELL	$23.58 - $44.68 $238,157 - $451,268	-10,100 Reduced 97.12%	300 $12,000
Q4 2022 Feb 14, 2023	BUY	$18.46 - $36.37 $191,984 - $378,248	10,400 New	10,400 $309,000

209

59.5M

450K

619K

Ticker NUVL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,977,800
Market Cap $3.55B
Description
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.